Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome

Sponsors

Lead Sponsor: Jonsson Comprehensive Cancer Center

Source Jonsson Comprehensive Cancer Center
Brief Summary

This phase II trial studies how well anakinra works in preventing severe chimeric antigen receptor T-cell-related encephalopathy syndrome after chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma that has come back or has not responded to treatment. Immunosuppressive therapy, such as anakinra, is used to decrease the body?s immune response, which may prevent severe chimeric antigen receptor T-cell-related encephalopathy syndrome.

Detailed Description

PRIMARY OBJECTIVES: I. To determine if it is feasible to accrue a sufficient number of study participants at one site, in order to justify expanding the trial to three additional sites (pilot study). II. To estimate the efficacy of anakinra in prevention of severe immune effector cell-associated neurotoxicity syndrome. syndrome (ICANS) (full study). SECONDARY OBJECTIVES: I. To estimate the impact that anakinra has on the efficacy of chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory lymphoma. II. To estimate the rate of subsequent ICANS development in patients who receive anakinra for grade >= 3 cytokine release syndrome (CRS) in the absence of ICANS. III. To estimate the duration of neurotoxicity in patients who receive anakinra. IV. To estimate the duration of severe neurotoxicity in patients who receive anakinra. V. To determine if anakinra causes persistent hepatotoxicity in patients receiving CAR T-cell for refractory lymphoma. VI. to evaluate the overall toxicity of anakinra in patients receiving CAR T-cell therapy for refractory lymphoma. EXPLORATORY OBJECTIVES: I. To evaluate CRS and ICANS grade by using the American Society for Blood and Marrow Transplantation (ASBMT) 2018 consensus grading for adults. II. To investigate changes in inflammatory markers including IL-1 and IL-6 in the peripheral blood during episodes of ICANS. III. To describe the electroencephalogram (EEG) changes that characterize ICANS. OUTLINE: Patients receive standard lymphodepleting therapy including fludarabine and cyclophosphamide on days -5 to -3, then receive axicabtagene ciloleucel CAR T-cell infusion. Patients with clinical evidence of ICANS of any grade, or CRS >= grade 3 receive anakinra subcutaneously (SC) every 6-12 hours for 12-36 doses over 9 days in the absence of unacceptable toxicity. After completion of study, patients are followed up at 30, 90, and 100 days, then at 6 months.

Overall Status Suspended
Start Date 2020-03-04
Completion Date 2022-12-01
Primary Completion Date 2021-12-01
Phase Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Number of patients who met the eligibility criteria to receive and did receive anakinra Up to 12 months
Rate of severe chimeric antigen receptor T-cell-related encephalopathy syndrome (ICANS) Up to 30 days
Secondary Outcome
Measure Time Frame
Objective response rate (ORR) Up to 90 days
Proportion of patients who received anakinra and develop ICAN Up to 30 days
Duration of neurotoxicity From first day of CRES of any grade to complete resolution of CRES, assessed up to 100 days
Duration of neurotoxicity From first day of ICANS of >= grade 3 to improvement of ICANS to < grade 3, assessed up to 100 days
Persistent hepatotoxicity Up to 100 days
Incidence of adverse events (AEs) Up to 100 days
Enrollment 36
Condition
Intervention

Intervention Type: Biological

Intervention Name: Anakinra

Description: Given SC

Arm Group Label: Prevention (anakinra, CAR T-cell therapy)

Intervention Type: Biological

Intervention Name: Axicabtagene Ciloleucel

Description: Given via infusion

Arm Group Label: Prevention (anakinra, CAR T-cell therapy)

Intervention Type: Drug

Intervention Name: Cyclophosphamide

Description: Given via infusion

Arm Group Label: Prevention (anakinra, CAR T-cell therapy)

Intervention Type: Drug

Intervention Name: Fludarabine

Description: Given via infusion

Arm Group Label: Prevention (anakinra, CAR T-cell therapy)

Other Name: Fluradosa

Intervention Type: Drug

Intervention Name: Fludarabine Phosphate

Description: Given via infusion

Arm Group Label: Prevention (anakinra, CAR T-cell therapy)

Eligibility

Criteria:

Inclusion Criteria: - Patients with relapsed or refractory large B-cell lymphoma that has progressed on two prior lines of therapy, who meet the indication for the Food and Drug Administration (FDA)-approved therapy axicabtagene ciloleucel - Large B-cell lymphoma includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma - The above includes patients with progressive or stable disease as the best response to the most recent treatment regimen or disease progression within 12 months after autologous hematopoietic stem cell transplantation - Patients with central nervous system (CNS) involvement of large B-cell lymphoma that originated outside of the CNS will be included (not primary CNS lymphoma) - Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 upper limit of normal - Total bilirubin =< 2.0 mg/dL - Creatinine clearance > 30 mL/min based on Cockcroft-Gault formula - Patients with human immunodeficiency virus (HIV) who have an undetectable viral load will be included - Deemed competent to make medical decisions Exclusion Criteria: - Patients who receive CAR T-cell therapy with a product other than axicabtagene ciloleucel - Primary CNS lymphoma - Transformed DLBCL from chronic lymphocytic leukemia (CLL) - Burkitt?s lymphoma - Bridging chemotherapy completed < 7 days prior to CAR T-cell lymphodepleting chemotherapy - In patients who receive bridging chemotherapy, positron emission tomography (PET)-computed tomography (CT) or CT of chest, abdomen, pelvis was not done after bridging chemotherapy prior lympho-depleting therapy - Most recent PET-CT or CT of all known disease is sites done more than 6 weeks prior to CAR T-cell infusion - Any individual CNS tumor mass > 2 cm - History of autologous hematopoietic stem cell transplantation administered less than 100 days prior to CAR T-cell infusion - History of allogeneic hematopoietic stem cell transplantation - Treatment with alemtuzumab within 6 months prior to leukapheresis, or treatment with clofarabine or cladribine within 3 months prior to leukapheresis - Less than 3 half-lives elapsed since receiving immune checkpoint inhibitor (pembrolizumab, ipilimumab, nivolumab, atezolizumab, etc.) - Presence of uncontrolled fungal, bacterial, or viral infection that require intravenous (IV) antimicrobial treatment - History of autoimmune disease resulting in end-organ damage, or autoimmune disease requiring systemic immunosuppressants or disease-modifying antirheumatic drug (DMARDs) within the past 6 months - Hypersensitivity to E. Coli-derived proteins - Patients with HIV who have a detectable viral load - Pregnant or nursing - Fertile women who decline use of contraception during the study period

Gender:

All

Minimum Age:

18 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
John M Timmerman, MD Principal Investigator UCLA / Jonsson Comprehensive Cancer Center
Overall Contact

Last Name: Caspian Oliai, MD

Phone: 310-206-8477

Phone Ext.: 30870

Email: [email protected]

Location
Facility: UCLA / Jonsson Comprehensive Cancer Center
Location Countries

United States

Verification Date

2021-06-01

Responsible Party

Type: Sponsor

Condition Browse
Number Of Arms 1
Arm Group

Label: Prevention (anakinra, CAR T-cell therapy)

Type: Experimental

Description: Patients receive standard lymphodepleting therapy including fludarabine and cyclophosphamide on days -5 to -3, then receive axicabtagene ciloleucel CAR T-cell infusion. Patients with clinical evidence of ICANS of any grade, or CRS >= grade 3 receive anakinra SC every 6-12 hours for 12-36 doses over 9 days in the absence of unacceptable toxicity.

Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Prevention

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News